News & Topics
Realization of chemo-immunotherapy using nano-DDS to dramatically enhances the efficacy of immune checkpoint inhibitors against glioblastoma
Kawasaki Institute of Industrial Promotion Innovation Center of NanoMedicine (Director General: Dr. Kazunori Kataoka, Location: Kawasaki-ku, Kawasaki City, Abbreviation: iCONM)demonstrated a new therapeutic option for glioblastoma (GBM), which is a type of brain tumors, in mice in a collaboration study with the Department of Bioengineering, Graduate School of Engineering, The University of Tokyo.
The contents of this research were published in ACS Nano (Impact Factor=14.588 in 2019), which was issued by the American Chemical Society (ACS).
At the press seminar held online on Tuesday, August 4, Dr. Kazunori Kataoka, Director General, Innovation Center of NanoMedicine, Dr. Hiroaki Kinoh, Principal Research Scientist, Kataoka/Kinoh Lab., Innovation Center of NanoMedicine, Dr. Horacio Cabral, Associate Professor, Department of Bioengineering, Graduate School of Engineering, The University of Tokyo and others took the rostrum, and there were the deep, enthusiastic and passionate discussions with journalists in science section, the general paper and biotech journals.
【Kazunori Kataoka, Director General iCONM】
【Hiroaki Kinoh, Principal Research Scientist】
【Horacio Cabral, Associate Professor】
【Web conference room】